A Study of TACE Combined With Atezolizumab Plus Bevacizumab or TACE Alone in Patients With Untreated Heaptocellular Carcionma

  • Cancer
  • Hepatocellular Carcinoma (HCC)
Please note that the recruitment status of the study at your site may differ from the overall study status because some study sites may recruit earlier than others.
Study Status:

Active, not recruiting

This study runs in
Cities
  • Aichi
  • Anhui
  • Beijing
  • Beijing City
  • Changsha City
  • Chengdu
  • Chiba
  • Chongqing
  • Fukuoka
  • Fuzhou
  • Fuzhou City
  • Guangzhou
  • Hangzhou
  • Harbin City
  • Hiroshima
  • Kanagawa
  • Nanjing
  • Nanjing City
  • Nanning
  • Osaka
  • Shanghai
  • Shenyang
  • Tianjin City
  • Tokyo
  • Xi'an
  • Zhengzhou Shi
Trial Identifier:

NCT04712643 ML42612

      Show study locations

      The source of the below information is public registry websites such as ClinicalTrials.gov, EuClinicalTrials.eu, ISRCTN.com, etc.. It has been summarised and edited into simpler language. For more information about this clinical study see the For Expert tab on the specific ForPatients page or follow these links to https://clinicaltrials.gov and/or https://euclinicaltrials.eu and/or https://www.isrctn.com.

      The below information is taken directly from public registry websites such as ClinicalTrials.gov, EuClinicalTrials.eu, ISRCTN.com, etc., and has not been edited.

      Results Disclaimer

      Study Summary

      This study will evaluate the efficacy and safety of atezolizumab plus bevacizumab combined with on-demand TACE compared to on-demand TACE alone in participants with hepatocellular carcinoma who are at high risk of poorer outcome following TACE treatment.

      Hoffmann-La Roche Sponsor
      Phase 3 Phase
      NCT04712643, ML42612 Trial Identifier
      Atezolizumab, Becavizumab, Transarterial chemoembolization (TACE) Treatments
      Hepatocellular Carcinoma Condition
      Official Title

      A Phase III, Open-Label, Randomized Study of On-Demand TACE Combined With Atezolizumab Plus Bevacizumab (Atezo/Bev) or On-Demand TACE Alone in Patients With Untreated Heaptocellular Carcionma

      Eligibility Criteria

      All Gender
      ≥18 Years Age
      No Healthy Volunteers
      Inclusion Criteria
      • Confirmed diagnosis of HCC by histology/ cytology or clinical criteria
      • Eligible for TACE treatment
      • No prior systemic therapy for HCC, especially immunotherapy
      • No prior locoregional therapy to the target lesion(s)
      • At least one measurable untreated lesion
      • ECOG Performance Status of 0-1
      • Child-Pugh class A
      Exclusion Criteria
      • Evidence of Vp3/4 and hepatic vein tumor thrombus (HVTT)
      • Evidence of extrahepatic spread (EHS)
      • Being a candidate for curative treatments
      • Any condition representing a contraindication to TACE as determined by the investigators
      • Active or history of autoimmune disease or immune deficiency
      • Untreated or incompletely treated esophageal and/or gastric varices with bleeding or high risk for bleeding
      • A prior bleeding event due to esophageal and/or gastric varices within 6 months prior to initiation of study treatment
      • Evidence of bleeding diathesis or significant coagulopathy

      For the latest version of this information please go to www.forpatients.roche.com

       

      Related Studies

      Use our search to find other trials on Genentech Clinical Trials in related disease areas.

      Hepatocellular Carcinoma (HCC)

      About Clinical Research

      What is a clinical trial? Why should I consider taking part in a clinical trial? And why does Genentech conduct clinical trials?

      Find out now